acp-211
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 14, 2025 (NCT07284667)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 2 Sponsor(trial)
Mechanism of action
- Glutamate NMDA receptorANTAGONIST
Glutamate NMDA receptor antagonist
- Glutamate receptor ionotropic, NMDA 2A (Grin2a) ↗
- Glutamate receptor ionotropic, NMDA 3B (Grin3b) ↗
- Glutamate receptor ionotropic, NMDA 2D (Grin2d) ↗
- Glutamate receptor ionotropic, NMDA 1 (Grin1) ↗
- Glutamate receptor ionotropic, NMDA 2B (Grin2b) ↗
- Glutamate receptor ionotropic, NMDA 2C (Grin2c) ↗
- Glutamate receptor ionotropic, NMDA3A (Grin3a) ↗
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07284667 | Phase 2 | Nov 14, 2025 | Acadia Pharmaceuticals |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Acadia Pharmaceuticals | For profit | 1 | 1 | 1 | 2025 |
1 organizations
Page 1 / 1